FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2286461840> ?p ?o ?g. }

• W2286461840 endingPage "150" @default.
• W2286461840 startingPage "145" @default.
• W2286461840 abstract "Abstract Background/aim A post‐marketing surveillance (PMS) study is being conducted to investigate the safety and effectiveness of the long‐term use of dabigatran etexilate (dabigatran) in Japanese patients with nonvalvular atrial fibrillation (NVAF). Results of an interim analysis of this prospective cohort study including patient characteristics and adverse drug reactions (ADRs) collected up to September 17, 2014 are reported here. Methods Patients with NVAF who began to receive dabigatran for the first time from December 2011 to November 2013 were enrolled at 1042 study sites in Japan. Clinical parameters included patient characteristics, dabigatran dose strength, concomitant medications and outcome events. All outcome events were collected as serious and non‐serious adverse events (AEs). ADRs were evaluated in this report. Pre‐defined safety events of special interest for intensive survey were serious and non‐serious outcome events such as myocardial infarction, as well as the total number of hemorrhage and gastrointestinal disorders. Results A total of 6772 patients were registered. The safety analysis set included 6148 patients; mean age was 70.8±9.9 (SD) years: 2323 patients (37.8%) were aged 75 years or older. Males accounted for 66.8% of the patients. Mean CHADS 2 score was 1.8±1.3; the CHADS 2 score was 0 in 13.6%, 1 in 31.3%, 2 in 25.9%, 3 in 14.9%, and 4 to 6 in 11.1% of the patients. Of the 6148 patients, 1701 patients (27.7%) were switchers from warfarin and 4407 patients (71.7%) were non‐switchers (OAC naïve patients). Treatment adherence was assessed for the first 3 months from the start of treatment for this analysis. Total 5656 patients (92.0%) reported taking dabigatran twice daily (bid) every day according to the label recommendation. During the follow up period [mean duration of follow up: 498±259 days (corresponding to 8386 patient‐years)], pre‐defined safety events of special interest for intensive survey (reported as serious ADRs) were: myocardial infarction, reported in 5 patients (0.06 per 100 patient‐years); serious hemorrhage, reported in 46 patients (0.55 per 100 patient‐years); and gastrointestinal disorders (non‐hemorrhagic), reported in 11 patients (0.13 per 100 patient‐years). Fifteen patients had ADRs with fatal outcome. Conclusions The interim findings from this 6148 patient PMS study further corroborate the favorable safety profile of dabigatran as demonstrated previously in controlled clinical trials. (ClinicalTrials.gov number, NCT01491178.)" @default.
• W2286461840 created "2016-06-24" @default.
• W2286461840 creator A5009936698 @default.
• W2286461840 creator A5011453870 @default.
• W2286461840 creator A5015689408 @default.
• W2286461840 creator A5025141510 @default.
• W2286461840 creator A5030012941 @default.
• W2286461840 creator A5036381262 @default.
• W2286461840 creator A5037947127 @default.
• W2286461840 creator A5039092553 @default.
• W2286461840 creator A5055983723 @default.
• W2286461840 creator A5072169946 @default.
• W2286461840 date "2016-01-16" @default.
• W2286461840 modified "2023-10-04" @default.
• W2286461840 title "Post-marketing surveillance on the long-term use of dabigatran in Japanese patients with nonvalvular atrial fibrillation: Preliminary report of the J-dabigatran surveillance" @default.
• W2286461840 cites W1984553148 @default.
• W2286461840 cites W1985967204 @default.
• W2286461840 cites W2011936209 @default.
• W2286461840 cites W2062786076 @default.
• W2286461840 cites W2063976695 @default.
• W2286461840 cites W2069426721 @default.
• W2286461840 cites W2083565910 @default.
• W2286461840 cites W2116526419 @default.
• W2286461840 cites W2136489990 @default.
• W2286461840 cites W2137878797 @default.
• W2286461840 cites W2313055962 @default.
• W2286461840 cites W4238531734 @default.
• W2286461840 doi "https://doi.org/10.1016/j.joa.2015.11.008" @default.
• W2286461840 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4823571" @default.
• W2286461840 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27092197" @default.
• W2286461840 hasPublicationYear "2016" @default.
• W2286461840 type Work @default.
• W2286461840 sameAs 2286461840 @default.
• W2286461840 citedByCount "23" @default.
• W2286461840 countsByYear W22864618402017 @default.
• W2286461840 countsByYear W22864618402018 @default.
• W2286461840 countsByYear W22864618402019 @default.
• W2286461840 countsByYear W22864618402020 @default.
• W2286461840 countsByYear W22864618402021 @default.
• W2286461840 crossrefType "journal-article" @default.
• W2286461840 hasAuthorship W2286461840A5009936698 @default.
• W2286461840 hasAuthorship W2286461840A5011453870 @default.
• W2286461840 hasAuthorship W2286461840A5015689408 @default.
• W2286461840 hasAuthorship W2286461840A5025141510 @default.
• W2286461840 hasAuthorship W2286461840A5030012941 @default.
• W2286461840 hasAuthorship W2286461840A5036381262 @default.
• W2286461840 hasAuthorship W2286461840A5037947127 @default.
• W2286461840 hasAuthorship W2286461840A5039092553 @default.
• W2286461840 hasAuthorship W2286461840A5055983723 @default.
• W2286461840 hasAuthorship W2286461840A5072169946 @default.
• W2286461840 hasBestOaLocation W22864618401 @default.
• W2286461840 hasConcept C126322002 @default.
• W2286461840 hasConcept C194828623 @default.
• W2286461840 hasConcept C197636746 @default.
• W2286461840 hasConcept C197934379 @default.
• W2286461840 hasConcept C2776301958 @default.
• W2286461840 hasConcept C2778810321 @default.
• W2286461840 hasConcept C2779161974 @default.
• W2286461840 hasConcept C2779384505 @default.
• W2286461840 hasConcept C535046627 @default.
• W2286461840 hasConcept C61943457 @default.
• W2286461840 hasConcept C71924100 @default.
• W2286461840 hasConcept C72563966 @default.
• W2286461840 hasConceptScore W2286461840C126322002 @default.
• W2286461840 hasConceptScore W2286461840C194828623 @default.
• W2286461840 hasConceptScore W2286461840C197636746 @default.
• W2286461840 hasConceptScore W2286461840C197934379 @default.
• W2286461840 hasConceptScore W2286461840C2776301958 @default.
• W2286461840 hasConceptScore W2286461840C2778810321 @default.
• W2286461840 hasConceptScore W2286461840C2779161974 @default.
• W2286461840 hasConceptScore W2286461840C2779384505 @default.
• W2286461840 hasConceptScore W2286461840C535046627 @default.
• W2286461840 hasConceptScore W2286461840C61943457 @default.
• W2286461840 hasConceptScore W2286461840C71924100 @default.
• W2286461840 hasConceptScore W2286461840C72563966 @default.
• W2286461840 hasIssue "2" @default.
• W2286461840 hasLocation W22864618401 @default.
• W2286461840 hasLocation W22864618402 @default.
• W2286461840 hasLocation W22864618403 @default.
• W2286461840 hasLocation W22864618404 @default.
• W2286461840 hasLocation W22864618405 @default.
• W2286461840 hasOpenAccess W2286461840 @default.
• W2286461840 hasPrimaryLocation W22864618401 @default.
• W2286461840 hasRelatedWork W1973989324 @default.
• W2286461840 hasRelatedWork W1994905407 @default.
• W2286461840 hasRelatedWork W2063976695 @default.
• W2286461840 hasRelatedWork W2108977729 @default.
• W2286461840 hasRelatedWork W2160502551 @default.
• W2286461840 hasRelatedWork W2161066565 @default.
• W2286461840 hasRelatedWork W2341835401 @default.
• W2286461840 hasRelatedWork W4254988178 @default.
• W2286461840 hasRelatedWork W1810372846 @default.
• W2286461840 hasRelatedWork W2344108540 @default.
• W2286461840 hasVolume "32" @default.
• W2286461840 isParatext "false" @default.
• W2286461840 isRetracted "false" @default.
• W2286461840 magId "2286461840" @default.
• W2286461840 workType "article" @default.